A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Recruiting
This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 patients will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +39 locations
Conditions: VEXAS, VEXAS Syndrome
Register for Updates
Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
NCT06886464
Recruiting
The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug. The main questions it aims to answer are: - whether cilastatin will prevent nephrotoxic AKI in hospitalized patients. Researchers will compare the drug cilastatin to a placebo (a look-alike substance that contains no drug) to see if drug cilastatin works to prevent AKI in ho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Calgary, Calgary, Alberta +1 locations
Conditions: Acute Kidney Injury
Register for Updates
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: The University of Alabama at Birmingham Clinical Research Unit (CRU), Birmingham, Alabama +98 locations
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Register for Updates
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461
Recruiting
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario +7 locations
Conditions: Melanoma
Register for Updates
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Physicians Research Group, LLC, Phoenix, Arizona +111 locations
Conditions: Pain
Register for Updates
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079
Recruiting
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Royal North Shore Hospital, Sydney, New South Wales +11 locations
Conditions: Neuroendocrine Tumors
Register for Updates
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298
Recruiting
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 80 participants will be randomized.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/11/2025
Locations: Urology Associates of Mobile, Mobile, Alabama +49 locations
Conditions: Prostatic Neoplasm
Register for Updates
Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking
NCT03909477
Recruiting
This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/11/2025
Locations: Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London, Ontario
Conditions: Cannabis Use, Cannabis Smoking, Marijuana Smoking, Marijuana Usage
Register for Updates
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
NCT05879432
Recruiting
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary, Calgary, Alberta +7 locations
Conditions: Acute Kidney Injury, Cardiac Surgery
Register for Updates
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study will open enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years will be permitted to enroll. Lastly, children aged 1 to 5 years will be permitted to enroll. This stud... Read More
Gender:
MALE
Ages:
Between 1 year and 17 years
Trial Updated:
08/11/2025
Locations: Intermountain - Primary Children's Hospital, Salt Lake City, Utah +59 locations
Conditions: Hemophilia A, Hemophilia B
Register for Updates
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/11/2025
Locations: Local Institution - 1029, Homewood, Alabama +382 locations
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
International CRDS Registry
NCT06508164
Recruiting
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: University of California, San Francisco, California +8 locations
Conditions: Calcium Release Deficiency Syndrome
Register for Updates